HOME CURRENT ISSUE TABLE OF CONTENTS ARCHIVE SEARCH SUBSCRIPTIONS JOBS FEEDBACK HELP		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moreau, M. Articles by Pelletier, J-P. Search for Related Content PubMed PubMed Citation Articles by Moreau, M. Articles by Pelletier, J-P.

Efficacy of licofelone in dogs with clinical osteoarthritis

¹ Companion Animal Research Group, Veterinary Teaching Hospital Centre, Faculty of Veterinary Medicine, University of Montreal, PO Box 5000, St Hyacinthe, Quebec, J2S 7C6, Canada
² Department of Biomedicine, Faculty of Veterinary Medicine, University of Montreal, PO Box 5000, St Hyacinthe, Quebec, J2S 7C6, Canada
³ Osteoarthritis Research Unit, University of Montreal Hospital Centre, Notre-Dame Hospital, 1560 Sherbrooke Street East, Montreal, Quebec, H2L 4M1, Canada

Correspondence: Correspondence to Professor Pelletier

To evaluate the effect of licofelone, an arachidonic acid substrate with combined inhibitory activity against 5-lipoxygenase and cyclooxygenases 1 and 2, a double-blind, randomised and placebo-controlled study was conducted in 33 client-owned dogs that were lame owing to hindlimb osteoarthritis. Seventeen of the dogs received a placebo and 16 were treated with 2·5 mg/kg licofelone twice a day for 28 days. The dogs' lameness was assessed on a visual analogue scale (VAS), and by force plate analyses at baseline and 14 and 28 days after starting the treatment. After 14 days the mean (se) change in peak vertical force in the licofelone-treated dogs (1·7 [0·8] per cent bodyweight) was significantly greater (P<0·05) than in the placebo-treated dogs (-0·3 [0·6] per cent bodyweight), and after 28 days the difference had increased. In contrast, the dogs' lameness, as assessed by the VAS values, had decreased significantly over baseline in both the treated and control groups.

This article has been cited by other articles:

				W. Albrecht, A. Unger, A. K. Nussler, and S. Laufer In Vitro Metabolism of 2-[6-(4-Chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] Acetic Acid (Licofelone, ML3000), an Inhibitor of Cyclooxygenase-1 and -2 and 5-Lipoxygenase Drug Metab. Dispos., May 1, 2008; 36(5): 894 - 903. [Abstract] [Full Text] [PDF]